TRIUMPH Observational Study

An observational study to investigate outcomes and post-treatment status after completion of study treatment in patients who participated in the investigator-initiated "Trastuzumab combIned with pertuzumab for patients with HER2 positive mCRC (TRIUMPH Study)"

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030220064

Enrollment

Registered

2022-05-17

Start date

2022-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with HER2 positive mCRC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who participated in the TRIUMPH study

Exclusion criteria

Exclusion criteria: Patients withdrawing consent for the TRIUMPH trial as of the end of April 2022

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression-free survival Duration of response Time to treatment failure	—

Contacts

Public ContactYoshiaki Nakamura

National Cancer Center Hospital East

triumph_core@east.ncc.go.jp+81-4-7133-1111

Outcome results